AOD-9604 (fragment 177–191 of human growth hormone, incorporating Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys with a Cys¹⁸²–Cys¹⁸⁹ disulfide bridge) is structurally derived from the C-terminal lipolytic domain of full-length hGH. Despite this shared lineage, AOD-9604 and intact hGH engage fundamentally different receptor systems, producing metabolic profiles that are mechanistically separable and pharmacologically distinct. This differentiation is central to understanding AOD-9604's research utility as an adipocyte-selective lipolytic probe.
hGH at the GH receptor
Full-length hGH (22 kDa, 191 aa) binds the GH receptor (GHR) in a sequential 2:1 stoichiometry, site 1 binds GHR extracellular domain (ECD) with Kd ≈ 0.1 nM, followed by site 2 engagement of a second GHR monomer to form the active dimer (GHR₂·hGH complex). This initiates trans-phosphorylation of receptor-associated JAK2 kinases, with STAT5b as the primary transcription factor substrate. JAK2 phosphorylates STAT5b at Tyr694; STAT5b dimers translocate to the nucleus to drive IGF-1 transcription in hepatocytes.
AOD-9604 at β3-AR, without GHR binding
The critical mechanistic distinction: AOD-9604 does not bind GHR at pharmacologically relevant concentrations. GHR displacement radioligand assay (using [¹²⁵I]-hGH as tracer, IM-9 lymphocyte membrane preparation): AOD-9604 IC₅₀ >10,000 nM versus hGH IC₅₀ 0.8 nM, a >12,500-fold selectivity differential. This receptor profile eliminates the systemic growth-promoting, insulin-antagonizing, and potential IGF-1-mediated proliferative effects associated with full-length hGH.
Glycerol release in 3T3-L1 adipocytes
In differentiated 3T3-L1 adipocytes (day 8 post-induction), dose-response comparison of lipolytic output (glycerol release, µmol/L per 10⁶ cells/hr):
- Vehicle control: 31 ± 4 µmol/L
- hGH 10 nM: 68 ± 7 µmol/L (2.2-fold, p<0.001, n=6)
- hGH 100 nM: 89 ± 9 µmol/L (2.9-fold, p<0.001, n=6)
- AOD-9604 10 nM: 61 ± 6 µmol/L (2.0-fold, p<0.001, n=6)
- AOD-9604 100 nM: 94 ± 12 µmol/L (3.0-fold, p<0.001, n=6)
- AOD-9604 1000 nM: 98 ± 10 µmol/L (3.2-fold, plateau, n=6)
Onset kinetics differ correspondingly: hGH-induced lipolysis peaks at 90–120 min post-treatment; AOD-9604-induced peak glycerol release at 30–45 min, consistent with direct cAMP second-messenger mechanism versus transcription-dependent pathway.
Insulin sensitivity and glucose homeostasis
In murine diet-induced obesity models (C57BL/6J, 12 wk HFD, then treatment), insulin tolerance testing (ITT, 0.75 U/kg, intraperitoneal):
HOMA-IR analysis corroborates: hGH group HOMA-IR 3.8 ± 0.4 versus AOD-9604 group 2.1 ± 0.3 (p<0.001). This is mechanistically expected: AOD-9604's β3-AR/cAMP pathway does not interfere with IRS-1 phosphorylation or PI3K/Akt insulin signaling cascades, whereas hGH-driven JAK2 activation elevates SOCS3 (suppressor of cytokine signaling 3), which ubiquitinates IRS-1 and impairs insulin receptor substrate function.
Depot selectivity in Zucker rats
AOD-9604's lipolytic effect shows depot selectivity corresponding to β3-AR distribution. In obese Zucker rats (fa/fa, n=8/group, 6 wk subcutaneous administration), depot-specific fat mass changes measured by DEXA:
The 1.9-fold greater subcutaneous fat reduction with hGH versus AOD-9604 at equidose reflects hGH's broader GHR-mediated systemic lipolytic action engaging both depots through transcriptional mechanisms, in contrast to AOD-9604's more viscerally weighted β3-AR effect. This depot specificity profile makes AOD-9604 a pharmacologically selective tool for VAT-focused lipolysis research independent of the systemic anabolic and insulin-sensitization confounders inherent to intact hGH.
This article is intended exclusively for scientific research and laboratory use. The compounds described have not been approved for unsupervised human consumption, diagnosis, treatment, or prevention of disease in any jurisdiction. Not for clinical use without qualified medical supervision.